Actym Therapeutics, Inc.
BERKELEY, CA · Founded 2017 · CIK 0001808722 · Biotech · Private
Engineered bacteria platform for delivering cancer immunotherapies
actymthera.com →- Grants
- —
- No SBIR or STTR on record
- Sector median: 1
- Raised
- $25M
- 2 Form D · Jul 2023
- 39 months since last filing
- Contracts
- —
- No federal contracts on record
- Patents
- 38
- 9 granted · 29 pending
- Sector median: 2
Capital Timeline
Federal ↑Equity ↓20192020202120222023
| Date | Event | Source | Amount |
|---|---|---|---|
| Private capital raised | Form D · SEC | $14,106,048 | |
| Private capital raised | Form D · SEC | $11,238,333 |
Form D · SEC
Peer position
| # | Company | Contracts | Disclosed equity |
|---|---|---|---|
| 2459 | GALECTIN THERAPEUTICS INC | — | $6.8M |
| 2460 | Eidos Therapeutics | — | $26M |
| 2461 | Expesicor Inc | — | — |
| 2462 | Actym Therapeutics, Inc. | — | $25M |
| 2463 | Verseon Corp | — | $25M |
| 2464 | Pharmazz, Inc. | — | $25M |
| 2465 | Abzena plc | — | $4.3M |
Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.
Founders & Team
- Benjamin ChenDirector
- Julie CherringtonDirector
- Kanad DasDirector
- James HuangDirector
- Amit KumarDirector · Promoter
- Ron MazumderDirector
- Christopher ThanosDirector · Executive Officer · Promoter
Patents
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofapplication
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Immunostimulatory Bacteria For Converting Macrophages Into A Phenotype Amenable To Treatment, And Companion Diagnostic For Identifying Subjects For Treatmentapplication
- Immunostimulatory Bacteria Engineered To Colonize Tumors, Tumor-resident Immune Cells, And The Tumor Microenvironmentgranted
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Engineered Immunostimulatory Bacterial Strains And Uses Thereofgranted
- Immunostimulatory Bacteria Delivery Platforms And Their Use For Delivery Of Therapeutic Productsapplication
- Immunostimulatory Bacteria Delivery Platforms And Their Use For Delivery Of Therapeutic Productsapplication
- Immunostimulatory Bacteria Engineered To Colonize Tumors, Tumor-resident Immune Cells, And The Tumor Microenvironmentapplication
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.